Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Average Recommendation of “Reduce” by Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have received an average rating of “Reduce” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $23.00.

Several equities analysts recently commented on the stock. Citigroup increased their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Truist Financial decreased their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Bank of America dropped their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Morgan Stanley began coverage on Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target on the stock. Finally, BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th.

Integra LifeSciences Price Performance

IART opened at $24.03 on Friday. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1.85 billion, a P/E ratio of -267.00, a PEG ratio of 0.82 and a beta of 1.15. The stock has a 50-day moving average price of $22.12 and a 200-day moving average price of $23.76. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. The business had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.76 earnings per share. Equities analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Integra LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of IART. Systematic Financial Management LP raised its position in shares of Integra LifeSciences by 53.9% in the 3rd quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company’s stock worth $11,115,000 after acquiring an additional 214,272 shares in the last quarter. Sachem Head Capital Management LP purchased a new stake in Integra LifeSciences in the third quarter worth $44,153,000. Centiva Capital LP bought a new position in Integra LifeSciences in the third quarter worth $192,000. Clearline Capital LP lifted its position in Integra LifeSciences by 226.8% during the third quarter. Clearline Capital LP now owns 230,397 shares of the life sciences company’s stock valued at $4,186,000 after buying an additional 159,903 shares during the period. Finally, Walleye Capital LLC boosted its holdings in shares of Integra LifeSciences by 758.7% during the 3rd quarter. Walleye Capital LLC now owns 234,506 shares of the life sciences company’s stock valued at $4,261,000 after buying an additional 207,196 shares in the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.